David D. Davidar - Nov 21, 2024 Form 4 Insider Report for GLOBUS MEDICAL INC (GMED)

Role
Director
Signature
/s/ Kelly G. Huller, Attorney-in-Fact
Stock symbol
GMED
Transactions as of
Nov 21, 2024
Transactions value $
-$3,400,050
Form type
4
Date filed
11/25/2024, 04:35 PM
Previous filing
Oct 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GMED Class A Common Stock Sale -$1.12M -13.2K -2.47% $85.00 523K Nov 21, 2024 Direct F1
transaction GMED Class A Common Stock Sale -$1.13M -13.3K -7.13% $85.00 173K Nov 21, 2024 By Davidar Family Irrevocable Trust F1, F2
transaction GMED Class A Common Stock Sale -$575K -6.77K -1.29% $85.00 516K Nov 22, 2024 Direct F1, F3
transaction GMED Class A Common Stock Sale -$573K -6.75K -3.91% $85.00 166K Nov 22, 2024 By Davidar Family Irrevocable Trust F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan dated December 23, 2023 executed by the reporting person.
F2 These shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is trustee of the trust.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at a price range of $85.00 - $85.10, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares at each separate price within the range set forth in footnote (2) of this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at a price range of $85.00 - $85.10, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares at each separate price within the range set forth in footnote (3) of this Form 4.